Concord Biotech IPO

Established presence across the complex fermentation value chain: : Over the last two decades since 2001, company has been able to build difficult-to-replicate technical expertise in the fermentation process.

Global leadership in immunosuppressant APIs: : They are one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology with a market share of over 20% by volume in 2021.

Manufacturing and R&D capabilities: : They have three manufacturing facilities in Gujarat. The facility in Dholka received the first inspection by USFDA in 2005, and the first inspection by the Government of Upper Bavaria, Germany for European Union Good Manufacturing Practice (EUGMP).

Diversified global customer base: : They have established long-standing relationships with key customers, including leading global generic pharmaceutical companies, They have over 200 customers in over 70 countries for both our API and formulation products.

Financial Performance: : For the financial years 2020, 2021 and 2022, our total revenue from operations was Rs. 5,123 million, Rs. 6,169.43 million and Rs. 7,129.33 million, respectively, representing a CAGR of 17.96% and EBITDA was Rs. 2,043 million, Rs. 3,271 million and Rs. 2,696.36 million, respectively.

Client Concentration: : They depend on a limited number of key customers for a substantial portion of revenues. Any significant reduction in demand from such customers may adversely affect business and results of operations.

High Competition: : The pharma industry is highly competitive. Inability to respond adequately to the competition may result in loss of market share.

Regulatory Risk: : They operate in highly regulated industry, any failure to obtain, maintain or renew licenses, permits and approvals can impact business and financial performance.

Pricing Pressure: : They face pricing pressure from their customers that can affect the ability to maintain or increase our product prices and impact profitability.

Government Incentives: : The company is currently entitled to govt’s PLI incentive schemes. Any decrease in or discontinuation in such schemes can affect their operations.